Skip to main content
Erschienen in:

28.02.2020

Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants

verfasst von: Alessandra Serrao, Benedetta Lucani, Giovanni Assanto Manfredi, Luciano Fiori, Erminia Baldacci, Simona Michela Aprile, Antonio Chistolini

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Anticoagulant therapy has undergone a significant change since direct oral anticoagulants (DOACs) introduction. Their obvious advantages including the fixed dose, the few interactions and less frequent controls, have made them the first choice anticoagulant therapy. More and more patients have therefore switched from therapy with vitamin K antagonists (VKAs) to DOACs. Aim of our study was to assess the satisfaction, quality of life (QoL) and therapy adherence of patients who switched from VKA to DOACs therapy. This single center study evaluated satisfaction and QoL of 107 patients who switched from VKA to DOACs therapy through Anti-Clot Treatment Scale and SF-36 respectively. The questionnaires were administered before therapy change, after 3 months of DOACs therapy and then annually. We also evaluated DOACs therapy adherence with a questionnaire administered each visit and through the measures of DOACs plasma levels. Patients’ satisfaction and QoL were high during VKA therapy, but with DOACs we observed an improvement after the first 3 months and then maintained over the time of DOACs therapy. DOACs adherence was excellent, also confirmed by DOACs plasma levels.
Literatur
1.
Zurück zum Zitat Anguita Sánchez M, Bertomeu Martínez V, Cequier Fillat Á (2015) CALIFA study researchers, quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol 68:761–768PubMed Anguita Sánchez M, Bertomeu Martínez V, Cequier Fillat Á (2015) CALIFA study researchers, quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol 68:761–768PubMed
2.
Zurück zum Zitat Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y (2014) Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 133:550–554PubMed Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y (2014) Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 133:550–554PubMed
3.
Zurück zum Zitat Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 383:955–962PubMed Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 383:955–962PubMed
4.
Zurück zum Zitat Yao X, Abraham NS, Sangaralingham LR et al (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 5(6):e003725PubMedPubMedCentral Yao X, Abraham NS, Sangaralingham LR et al (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 5(6):e003725PubMedPubMedCentral
5.
Zurück zum Zitat Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808PubMed Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808PubMed
6.
Zurück zum Zitat EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510 EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510
7.
Zurück zum Zitat Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352PubMed Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352PubMed
8.
Zurück zum Zitat Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH, AUGUSTUS Investigators (2019) Antithrombotic therapy after acute coro- nary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524PubMed Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH, AUGUSTUS Investigators (2019) Antithrombotic therapy after acute coro- nary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524PubMed
9.
Zurück zum Zitat Sherwood MW, Cyr DD, Jones WS et al (2016) Use of dual antiplatelet therapy and patient outcomes in those undergoing percutaneous cor-onary intervention. The ROCKET AF Trial. JACC Cardiovasc Interv 9:1694–1702PubMedPubMedCentral Sherwood MW, Cyr DD, Jones WS et al (2016) Use of dual antiplatelet therapy and patient outcomes in those undergoing percutaneous cor-onary intervention. The ROCKET AF Trial. JACC Cardiovasc Interv 9:1694–1702PubMedPubMedCentral
10.
Zurück zum Zitat Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524PubMed Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524PubMed
11.
Zurück zum Zitat Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthro-plasty. N Engl J Med 358:2765–2775PubMed Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthro-plasty. N Engl J Med 358:2765–2775PubMed
12.
Zurück zum Zitat Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for throm-boprophylaxis after hip replacement. N Engl J Med 363:2487–2498PubMed Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for throm-boprophylaxis after hip replacement. N Engl J Med 363:2487–2498PubMed
13.
Zurück zum Zitat Eriksson BI, Dahl OE, Rosencher N et al (2015) Oral dabigatran etexilate versus enoxa-parin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 random-ized trials. Thromb J 13:36PubMedPubMedCentral Eriksson BI, Dahl OE, Rosencher N et al (2015) Oral dabigatran etexilate versus enoxa-parin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 random-ized trials. Thromb J 13:36PubMedPubMedCentral
14.
Zurück zum Zitat Ashburner JM, Singer DE, Lubitz SA, Borowsky LH, Atlas SJ (2017) Changes in use of anticoagulation in patients with atrial fibrillation within a primary care network associated with the introduction of direct oral anticoagulants. Am J Cardiol 120(5):786–791PubMed Ashburner JM, Singer DE, Lubitz SA, Borowsky LH, Atlas SJ (2017) Changes in use of anticoagulation in patients with atrial fibrillation within a primary care network associated with the introduction of direct oral anticoagulants. Am J Cardiol 120(5):786–791PubMed
15.
Zurück zum Zitat Van den Heuvel JM, Hovels AM, Buller HR et al (2018) NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in the Netherlands. Thromb J 16:7PubMedPubMedCentral Van den Heuvel JM, Hovels AM, Buller HR et al (2018) NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in the Netherlands. Thromb J 16:7PubMedPubMedCentral
16.
Zurück zum Zitat Hirschl M, Kundi M (2019) Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation—a network meta-analysis of real-world data. Vasa 48(2):134–147PubMed Hirschl M, Kundi M (2019) Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation—a network meta-analysis of real-world data. Vasa 48(2):134–147PubMed
17.
Zurück zum Zitat Cano SJ et al (2012) The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes 10:120PubMedPubMedCentral Cano SJ et al (2012) The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes 10:120PubMedPubMedCentral
18.
Zurück zum Zitat Almeida GQ et al (2011) Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes 9:91PubMedCentral Almeida GQ et al (2011) Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes 9:91PubMedCentral
19.
Zurück zum Zitat Krousel-Wood M, Joyce C, Holt EW, Levitan EB, Dornelles A, Webber LS, Muntner P (2013) Development and evaluation of a self-report tool to predict low pharmacy refill adherence in elderly patients with uncontrolled hypertension. Pharmacotherapy 33(8):798–811PubMedPubMedCentral Krousel-Wood M, Joyce C, Holt EW, Levitan EB, Dornelles A, Webber LS, Muntner P (2013) Development and evaluation of a self-report tool to predict low pharmacy refill adherence in elderly patients with uncontrolled hypertension. Pharmacotherapy 33(8):798–811PubMedPubMedCentral
20.
Zurück zum Zitat Samuelson BT, Cuker A, Siegal DM et al (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 151(1):127–138PubMed Samuelson BT, Cuker A, Siegal DM et al (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 151(1):127–138PubMed
21.
Zurück zum Zitat PRADAXA® (dabigatran) drug c, Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292–303 PRADAXA® (dabigatran) drug c, Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292–303
22.
Zurück zum Zitat Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):675-86. https://doi.org/10.2165/11595320-000000000-00000. Erratum in: Clin Pharmacokinet 2012 51(2):136 Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):675-86. https://​doi.​org/​10.​2165/​11595320-000000000-00000. Erratum in: Clin Pharmacokinet 2012 51(2):136
24.
Zurück zum Zitat Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873–880PubMed Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873–880PubMed
26.
Zurück zum Zitat Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 33:2719–2747PubMed Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 33:2719–2747PubMed
27.
Zurück zum Zitat Paravattil B, Elewa H (2018) Approaches to direct oral anticoagulant selection in practice. J Cardiovasc Pharmacol Ther 24:1074248418793137 Paravattil B, Elewa H (2018) Approaches to direct oral anticoagulant selection in practice. J Cardiovasc Pharmacol Ther 24:1074248418793137
28.
Zurück zum Zitat Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497PubMed Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497PubMed
29.
Zurück zum Zitat Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L et al (2014) Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 167:810–817PubMedPubMedCentral Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L et al (2014) Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 167:810–817PubMedPubMedCentral
30.
Zurück zum Zitat Solla-Ruiz I, Villanueva-Benito I, Paredes-Galán E, Salterain-González N, Oria-González G, De La Cuesta-Arzamendi F, Querejeta-Iraola R (2019) Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study. Thromb Res 179:20–27PubMed Solla-Ruiz I, Villanueva-Benito I, Paredes-Galán E, Salterain-González N, Oria-González G, De La Cuesta-Arzamendi F, Querejeta-Iraola R (2019) Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study. Thromb Res 179:20–27PubMed
31.
Zurück zum Zitat Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J (2013) Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 168:2540–2547PubMed Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J (2013) Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 168:2540–2547PubMed
32.
Zurück zum Zitat Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S (2016) Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol 32:747–753PubMed Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S (2016) Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol 32:747–753PubMed
33.
Zurück zum Zitat Hanon O, Chaussade E, Gueranger P, Gruson E, Bonan S, Gay A (2016) Patient-reported treatment satisfaction with rivaroxaban for stroke prevention in atrial fibrillation. A French Observational Study, the SAFARI Study. PLoS ONE 11(12):e0166218PubMedPubMedCentral Hanon O, Chaussade E, Gueranger P, Gruson E, Bonan S, Gay A (2016) Patient-reported treatment satisfaction with rivaroxaban for stroke prevention in atrial fibrillation. A French Observational Study, the SAFARI Study. PLoS ONE 11(12):e0166218PubMedPubMedCentral
34.
Zurück zum Zitat Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, De la Figuera-Von WM, Sánchez-López E, Gil-Gil I, Márquez-Rivero S, Working Group on Compliance, and Inertia. Spanish Society of Hypertension (2017) Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance. Qual Life Res 26(3):647–654PubMed Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, De la Figuera-Von WM, Sánchez-López E, Gil-Gil I, Márquez-Rivero S, Working Group on Compliance, and Inertia. Spanish Society of Hypertension (2017) Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance. Qual Life Res 26(3):647–654PubMed
Metadaten
Titel
Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants
verfasst von
Alessandra Serrao
Benedetta Lucani
Giovanni Assanto Manfredi
Luciano Fiori
Erminia Baldacci
Simona Michela Aprile
Antonio Chistolini
Publikationsdatum
28.02.2020
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02070-2

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Auf einen Myokardinfarkt folgt häufig eine Herzinsuffizienz

Ein erneuter Myokardinfarkt sowie die Entwicklung einer Herzinsuffizienz sind wesentliche Komplikationen nach einem akuten Myokardinfarkt. Eine US-amerikanische Studie zeigt insbesondere ein hohes Risiko für die Entwicklung einer Herzinsuffizienz auf, von der nahezu ein Viertel der Patienten betroffen war.

Aerobes Training hilft bei Fibromyalgie

Sport im aeroben Bereich ist ein veritables Mittel, um die Schmerzen von Patienten mit Fibromyalgie zu reduzieren, wie eine Metaanalyse zeigt. Frequenz, Dauer und Intensität der Übungen geben den Ausschlag.

Kopfschmerzen: Arteriendissektion? Die wichtigsten Verdachtsmomente

Bei plötzlich auftretenden, ungewöhnlichen Kopfschmerzen, aber auch bekannten Kopfschmerzen, deren Charakter sich verändert, sollte an eine Arteriendissektion gedacht werden. Eine Literaturübersicht zeigt, wie vielfältig die Konstellationen sein können.

Bei Gewichtsschwankungen steigt das Risiko für Nierenschäden

Wiederholtes Ab- und Zunehmen kann der Gesundheit schaden: Bei Menschen mit Typ-1-Diabetes gehen Jo-Jo-Effekte u. a. mit einem beschleunigten Verlust von Nierenfunktion einher – unabhängig vom mittleren Gewicht und von etablierten Risikofaktoren. 

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.